Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis

Leukemia Research

Volumn 38, Issue 3, 2014, Pages 304-309

  Rojas, Silvia M ^a   Díez Campelo, María ^a   Luño, Elisa ^b   Cabrero, Mónica ^a   Pedro, Carme ^c   Calabuig, Marisa ^d   Nomdedeu, Benet ^e   Cedena, Teresa ^f   Arrizabalaga, Beatriz ^g   García, Marta ^h   Cerveró, Carlos ⁱ   Collado, Rosa ^j   Azaceta, Gemma ^k   Ardanaz, Ma Teresa ^l   Muñoz, Juan Antonio ^m   Xicoy, Blanca ⁿ   Rodríguez, Ma José Requena ^o   Bargay, Joan ^p   Morell, Ma Jesús Arilla ^q   Simiele, Adriana ^r   del Cañizo, Consuelo ^a   more..

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g HOSPITAL DE CRUCES   (Spain)

^h Consorcio Sanitario de Terrasa ^*  (Spain)

ⁱ HOSPITAL VIRGEN DE LA LUZ   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^k Hospital Universitario Clínico de Zaragoza   (Spain)

^l HOSPITAL TXAGORRITXU   (Spain)

^m HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

ⁿ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^o HOSPITAL SEVERO OCHOA   (Spain)

^p HOSPITAL SON LLÀTZER   (Spain)

^q Hospital Sagunto   (Spain)

^r Epilepsy Unit   (Spain)

more..

Author keywords

Del(5q); Hb level; Myelodysplastic syndrome; Survival; Transfusion dependence

Indexed keywords

DEL(5Q); HB LEVEL; MYELODYSPLASTIC SYNDROME; SURVIVAL; TRANSFUSION DEPENDENCE;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THALIDOMIDE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84894286265     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.11.005     Document Type: Article

References (27)

1. Tefferi A., Vardiman J.W. Myelodisplastic syndromes. N Engl J Med 2009, 361(19):1872-1885.
2. Greenberg P., Cox C., LeBeau M.M., et al. International Scoring System for evaluating prognosis in Myelodysplastic syndromes. Blood 1997, 89(6):2079-2088.
3. Greenberg P.L., Tuechler H., Schanz J., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012, 120(12):2454-2465.
4. Van den Berghe H., Cassiman J.J., David G., Fryns J.P., Michaux J.L., Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 1974, 251:437-443.
5. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100(7):2292-2302.
6. Patnaik M.M., Lasho T.L., Finke C.M., et al. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia 2010, 24(7):1283-1290.
7. Nimer S.D., Golde D.W. The 5q- abnormality. Blood 1987, 70(6):1705-1712.
8. Boultwood J., Lewis S., Wainscoat J.S. The 5q- syndrome. Blood 1994, 84(10):3253-3260.
9. Giagounidis A.A., Germing U., Wainscoat J.S., Boultwood J., Aul C. The 5q syndrome. Hematology 2004, 9(4):271-277.
10. Giagounidis A.A., Germing U., Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res 2006, 12(1):5-10.
11. Germing U., Lauseker M., Hildebrandt B., et al. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q). A multicenter study. Leukemia 2012, 26(6):1286-1292.
12. Malcovati L., Germing U., Kuendgen A., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:350-3510.
13. Cox D.R. Regression models and life-tables. J Roy Stat Soc B 1972, 34:187-220.
14. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
15. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
16. Giagounidis A.A.N., Germing U., Haase S., et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 2004, 18:113-119.
17. Mathew P., Tefferi A., Dewald G.W., et al. The 5q- syndrome: a single-institution study of 43 consecutive patients. Blood 1993, 81:1040-1045.
18. Haase D., Germing U., Schanz J., et al. New Insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110(13):4385-4395.
19. Gonzalez-Porras J.R., Cordoba I., Such E., et al. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. Cancer 2011, 117(24):5529-5537.
20. Kantarjian H., Fenaux P., Sekeres M.A., et al. Safety and efficacy of romiplostim in patients with lower-risk Myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010, 28(3):437-444.
21. Garcia-Manero G., Shan J., Faderl S., et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008, 22:538-543.
22. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355(14):1456-1465.
23. Fenaux P., Giagounidis A., Selleslag D., et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusiondependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del 5q. Blood 2011, 118:3765-3776.
24. Raza A., Reeves J.A., Feldman E.J., et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008, 111(1):86-93.
25. Mallo M., Cervera J., Schanz J., et al. Impact adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia 2011, 25:110-120.
26. Jonasova A., Cermak J., Vondrakova J., et al. Thrombocytopenia at diagnosis as important negative prognostic marker in isolated 5q- MDS (IPSS low and intermediate-1). Leuk Res 2012, 36(12):e222-e224.
27. Mallo M., del Rey M., Ibañez M., et al. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. Br J Haematol July 2013, 162(1):74-86.